FDA Cites Blood-Clot Risk Tied to Bayer AG Birth-Control Pills

U.S. regulators warned there may be an increased risk of blood clots connected with birth-control pills made by Bayer AG, and said the issue will be further evaluated in a meeting with advisers in December. Women taking pills containing the hormone drospirenone were 74 percent more likely to experience clots than those on low- estrogen pills, the Food and Drug Administration said in a report released today. An FDA advisory committee will meet Dec. 8 to discuss the findings. Sales of the Yaz family of birth-control pills fell 13 percent in 2010 to 1.11 billion euros ($1.57 billion), making them the company’s second-biggest drug. North American revenue from the pills has fallen as the German drugmaker, based in Leverkusen, faces competition from generics made by Teva Pharmaceutical Industries Ltd.

MORE ON THIS TOPIC